AstraZeneca

The idiopathic pulmonary fibrosis market is projected to grow from $3.89 billion in 2023 to $5.24 billion in 2028 at a CAGR of 6.2%, driven by factors like an aging population, limited treatment options, and advancements in diagnostic techniques. Key trends include product innovation and the rise of targeted therapies.

Life sciences sector resilient despite challenges; significant investments in ADCs, CGTs, AI, and CDMOs. ADCs and CGTs driving growth, with China leading in clinical trials and innovation. AI transforming drug discovery and clinical trials. APAC region dominating clinical trials, especially in oncology. China's biopharma sector booming, attracting global investments. CDMOs adopting digital revolution and AI for agile manufacturing. BIOSECURE Act impacting Chinese biotech companies, benefiting Indian CDMOs.

DelveInsight's 'Graft versus host disease Pipeline Insight 2024' covers 60+ companies and 65+ pipeline drugs, including clinical and nonclinical stage products, with a focus on therapeutics assessment by product type, stage, route of administration, and molecule type. Key companies and promising therapies in development are highlighted.

Amgen's MariTide, an experimental obesity treatment, showed a 20% weight loss in trials but common side effects like nausea and vomiting limit its competitiveness. Eli Lilly and Novo Nordisk's next-gen drugs, potentially achieving 25% weight loss, dominate the market. MariTide's antibody-linked peptide mechanism offers durability but faces Phase III trials. Amgen's stock fell 12.3% post-report, reflecting market skepticism.

Hutchmed renews contract with China's NHSA; Orpathys (savolitinib), an oral MET TKI for NSCLC with MET exon 14 skipping alterations, remains in the NRDL until Jan 1, 2025, under current terms. Orpathys, jointly developed by Hutchmed and AstraZeneca, is the first selective MET inhibitor in China and the NRDL.

Capivasertib (Truqap) combined with abiraterone acetate (Zytiga) and androgen deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) in PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) patients, according to the phase 3 CAPItello-281 trial. The safety profile remained consistent with known profiles of each agent, and while overall survival (OS) data were immature, a trend favored the capivasertib regimen. Results will be presented at a future medical conference.

Daiichi Sankyo plans to build a $152 million facility in Shanghai to produce antibody-drug conjugates for cancer treatments in response to growing Chinese demand.

A study in The Lancet Respiratory Medicine suggests benralizumab, an injection, may be a breakthrough treatment for asthma and COPD flare-ups, reducing treatment failure rates and side-effects compared to steroids like prednisolone.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.